Drug
Argx 119
Argx 119: highest development phase Phase 2, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARGX-119 NCT06441682 | Phase 2 | Amyotrophic Lateral Sclerosis |
Latest
No recent events.
Follow Argx 119 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.